Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Infectious Disease and Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD209 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD209 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD209 Products |
| Gene Delivery | CD209 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. High-titer particles. |
View CD209 Products |
| Benchmark Ab | Anti-CD209 Recombinant Antibody Sequence-verified positive control. Recombinant production ensures batch-to-batch consistency. |
View CD209 Products |
| Validator | CD209 siRNA Set Target-specific knockdown verification for functional assay validation. |
View CD209 Products |
| Related Target A | CD207 (Langerin) Critical C-type lectin for off-target and selectivity counter-screening. |
View CD207 Products |
| Related Target B | CD206 (Mannose Receptor) Co-expressed on subsets of dendritic cells and macrophages; essential for selectivity profiling. |
View CD206 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-Dependent Conformation Loss | HEK293 expression system preserves native folding and post-translational glycosylation required for functional C-type lectin assays. |
| Subfamily Off-Target Binding (CD207/CD206) | Fully sequence-verified CD207 and CD206 homolog proteins available for rigorous counter-screening panels. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant positive controls included. |
| False Positives in Cell Assays | Validated siRNA sets included for target-specific knockdown verification. |
Live CD209 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD209 (DC-SIGN) therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to targeted antigen delivery systems and viral entry inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting dendritic cell-specific vaccine conjugation and immune modulation in oncology and infectious disease. The complex oligomeric state of CD209 requires high-fidelity reagents that mimic native tetrameric presentation to ensure clinical translation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Dendritic Cell Vaccines | Academic Institutes, Biotech Consortia | Cancer, HIV-1, Hepatitis C | Internalization Assay (Requires HEK293-expressed CD209 ECD-Fc with native glycosylation) |
| Glycomimetic Inhibitors | Pharma & Specialty Biotechs | Infectious Diseases, Inflammation | Competitive Binding Assay (Requires high-purity CD209 protein and validated benchmark antibodies) |
| Bispecific Antibodies | Immunotherapy Developers | Solid Tumors, Tolerogenic Vaccines | Selectivity Screening (Requires CD209 vs CD207/CD206 counter-screening panels) |